Results 171 to 180 of about 9,443,204 (302)

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

Differences in physiological response to an oral glucose tolerance test in adult Maasai men and women. [PDF]

open access: yesActa Diabetol
Christensen DL   +11 more
europepmc   +1 more source

Short‐term clinical responses in horses and ponies treated with canagliflozin: A clinical field study

open access: yesEquine Veterinary Journal, EarlyView.
Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom   +3 more
wiley   +1 more source

Association of Post-Oral Glucose Tolerance Test Hypoglycaemia With Clinical Features, Incident Diabetes and Mortality in the Di@bet.es Cohort. [PDF]

open access: yesDiabetes Obes Metab
González-Vidal T   +14 more
europepmc   +1 more source

Heterogeneity in glucose response curves during an oral glucose tolerance test and associated cardiometabolic risk

open access: yesEndocrine, 2017
A. Hulman   +18 more
semanticscholar   +1 more source

Pancreatic α‐cell dysfunction associated with equine insulin dysregulation

open access: yesEquine Veterinary Journal, EarlyView.
Abstract Background Insulin dysregulation (ID) in horses is characterised by insulin resistance and exaggerated insulin responses, yet the underlying endocrine mechanisms remain incompletely understood. In humans, α‐cell dysfunction characterised by exaggerated glucagon secretion contributes to metabolic disease; however, the role of pancreatic α‐cell ...
Sanna Lindåse   +3 more
wiley   +1 more source

Evaluation of a new immunoassay for measuring equine serum insulin and plasma adrenocorticotrophic hormone: A method comparison study

open access: yesEquine Veterinary Journal, EarlyView.
Abstract Background Insulin dysregulation (ID) and pituitary pars intermedia dysfunction (PPID) are common equine endocrinopathies detected by measurement of circulating insulin and adrenocorticotrophic hormone (ACTH) concentrations. Different assays may yield variable results, limiting comparability.
Nicola J. Menzies‐Gow   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy